Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia

Figures & data

Figure 1. Factors that can predict a better outcome at different time points for RUNX1-RUNX1T1 (A), CBFB-MYH11 (B) and NPM1 (C), respectively.

Table 1. Part of molecular alterations that are more controversial whether they can be used as a marker of MRD. 1 point for supporting opinions and −1 point for opposing opinions.

Molecular alterations	Supporting scores								Opposing scores							Total score
	①	②	③	④	⑤	⑥	⑦	⑧	①	②	③	④	⑤	⑥	⑦
MLL-PTD	√				√			√					√			2
WT1		√	√	√	√				√			√				2
FLT3		√				√	√						√	√		1
RAS			√										√			0
EVI1	√	√						√	√			√		√		0
DATm	√		√							√	√					0
IDH1/2						√		√				√	√		√	–1